

# Dorothee Nickles

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11619693/publications.pdf>

Version: 2024-02-01

15  
papers

8,079  
citations

687363

13  
h-index

1058476

14  
g-index

15  
all docs

15  
docs citations

15  
times ranked

13332  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Molecular determinants of response to PD-L1 blockade across tumor types. <i>Nature Communications</i> , 2021, 12, 3969.  | 12.8 | 79        |
| 2  | Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment. <i>Cancer Research</i> , 2019, 79, 1493-1506.   | 0.9  | 118       |
| 3  | Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models. <i>Cancer Immunology Research</i> , 2019, 7, 963-976.  | 3.4  | 36        |
| 4  | Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation. <i>Cell Death and Differentiation</i> , 2019, 26, 2416-2429.  | 11.2 | 25        |
| 5  | TGF $\beta$ 2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <i>Nature</i> , 2018, 554, 544-548.  | 27.8 | 3,359     |
| 6  | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.  | 30.7 | 900       |
| 7  | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , 2016, 387, 1909-1920. | 13.7 | 3,077     |
| 8  | Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)., 2015, 3, .  |      | 12        |
| 9  | Whole genome sequences of 2 octogenarians with sustained cognitive abilities. <i>Neurobiology of Aging</i> , 2015, 36, 1435-1438.  | 3.1  | 1         |
| 10 | Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients. <i>Journal of Immunology</i> , 2014, 193, 580-586.  | 0.8  | 223       |
| 11 | The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease. <i>Clinical Immunology</i> , 2014, 151, 16-24.                                     | 3.2  | 49        |
| 12 | Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. <i>Human Molecular Genetics</i> , 2013, 22, 4194-4205.  | 2.9  | 81        |
| 13 | A Genome-Wide RNA Interference Screen Identifies Caspase 4 as a Factor Required for Tumor Necrosis Factor Alpha Signaling. <i>Molecular and Cellular Biology</i> , 2012, 32, 3372-3381.  | 2.3  | 36        |
| 14 | In depth comparison of an individual's DNA and its lymphoblastoid cell line using whole genome sequencing. <i>BMC Genomics</i> , 2012, 13, 477.  | 2.8  | 34        |
| 15 | An RNAi screen identifies USP2 as a factor required for TNF $\alpha$ -induced NF $\kappa$ B signaling. <i>International Journal of Cancer</i> , 2011, 129, 607-618.  | 5.1  | 49        |